The Randomized And Controlled Non-inferiority Trial to Evaluate Safety and Clinical Efficacy of the SurVeil Drug-Coated Balloon iN the Treatment of Subjects with Stenotic Lesions of the Femoropopliteal Artery Compared to the Medtronic IN.PACT Admiral Drug-Coated Balloon
Recruiting
99 years or below
All
50 participants needed
1 Location
Brief description of study
Prospective, multi-center, single-blind, randomized, controlled, noninferiority clinical trial. The trial will randomize approximately 446 subjects (at approximately 60 sites in the US and 18 sites outside the US) with symptomatic PAD due to stenoses of the femoral and/or popliteal arteries. Subjects meeting eligibility criteria will be randomized 1:1 to treatment with either the SurVeil DCB or the IN.PACT Admiral DCB, and followed for 60 months.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: TBD
-
Age: 99 years or below
-
Gender: All
Updated on
19 Feb 2024.
Study ID: 830129